Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX-115 in Type 2 Diabetes and Nephropathy
NCT04534439Phase 2Completed
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- Aug 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of isuzinaxib in diabetic nephropathy (DN), sponsored by AptaBio Therapeutics Inc.. Started Aug 2020; status: completed.
02
Drugs
isuzinaxib
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04534439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534439.